<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Enanta Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc</link>
<description>Latest news and press releases for Enanta Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/enanta-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835638378dffbe2df0ef482.webp</url>
<title>Enanta Pharmaceuticals Inc</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc</link>
</image>
<item>
<title>Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-announces-first-participant-dosed-in-phase-1-clinical-trial-of-edp-978-an-oral-once-daily-kit-inhibitor-in-development-for-the-treatment-of-urticaria</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-announces-first-participant-dosed-in-phase-1-clinical-trial-of-edp-978-an-oral-once-daily-kit-inhibitor-in-development-for-the-treatment-of-urticaria</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>Phase 1 Study Will Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EDP-978 in Healthy Volunteers Topline Data Expected in Q4 2026</description>
</item>
<item>
<title>Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-to-present-data-for-zelicapavir-an-oral-once-daily-n-protein-inhibitor-in-development-for-the-treatment-of-respiratory-syncytial-virus-at-escmid-global-2026</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-to-present-data-for-zelicapavir-an-oral-once-daily-n-protein-inhibitor-in-development-for-the-treatment-of-respiratory-syncytial-virus-at-escmid-global-2026</guid>
<pubDate>Tue, 07 Apr 2026 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., April 07, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of (RSV) have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21, 2025</description>
</item>
<item>
<title>Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule</description>
</item>
<item>
<title>Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-to-present-at-the-citizens-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-to-present-at-the-citizens-life-sciences-conference</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule</description>
</item>
<item>
<title>Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-present-preclinical-data-120000095</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-present-preclinical-data-120000095</guid>
<pubDate>Tue, 10 Feb 2026 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., February 10, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company’s KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting</description>
</item>
<item>
<title>Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-reports-financial-results-210100809</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-reports-financial-results-210100809</guid>
<pubDate>Mon, 09 Feb 2026 21:01:00 GMT</pubDate>
<description>WATERTOWN, Mass., February 09, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal first quarter ended December 31, 2025.</description>
</item>
<item>
<title>Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-provides-research-development-120000386</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-provides-research-development-120000386</guid>
<pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., January 08, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs and highlighted upcoming key milestones for 2026.</description>
</item>
<item>
<title>Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-present-44th-annual-120000533</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-present-44th-annual-120000533</guid>
<pubDate>Mon, 05 Jan 2026 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., January 05, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:00 p.m. PT in San Francisco, CA.</description>
</item>
<item>
<title>Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-reports-financial-results-210100315</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-reports-financial-results-210100315</guid>
<pubDate>Mon, 17 Nov 2025 21:01:00 GMT</pubDate>
<description>WATERTOWN, Mass., November 17, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2025.</description>
</item>
<item>
<title>Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-participate-upcoming-investor-120000340</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-participate-upcoming-investor-120000340</guid>
<pubDate>Tue, 04 Nov 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., November 04, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December.</description>
</item>
<item>
<title>Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-presents-data-zelicapavir-110000191</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-presents-data-zelicapavir-110000191</guid>
<pubDate>Mon, 20 Oct 2025 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., October 20, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that new data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, its oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2025 being held October 19 – 22,</description>
</item>
<item>
<title>Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-present-data-zelicapavir-110000185</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-present-data-zelicapavir-110000185</guid>
<pubDate>Tue, 07 Oct 2025 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., October 07, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it’s oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2025 being held October 19 - 22, 20</description>
</item>
<item>
<title>Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-announces-closing-upsized-200100270</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-announces-closing-upsized-200100270</guid>
<pubDate>Thu, 02 Oct 2025 20:01:00 GMT</pubDate>
<description>WATERTOWN, Mass., October 02, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that it has closed its previously announced underwritten public offering of 7,475,000 shares of its common stock, which includes 975,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $10.0</description>
</item>
<item>
<title>Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-announces-pricing-upsized-010000571</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-announces-pricing-upsized-010000571</guid>
<pubDate>Wed, 01 Oct 2025 01:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., October 01, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of custom</description>
</item>
<item>
<title>Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-announces-proposed-public-201100318</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-announces-proposed-public-201100318</guid>
<pubDate>Tue, 30 Sep 2025 20:11:00 GMT</pubDate>
<description>WATERTOWN, Mass., September 30, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its co</description>
</item>
<item>
<title>Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-reports-positive-topline-103000555</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-reports-positive-topline-103000555</guid>
<pubDate>Mon, 29 Sep 2025 10:30:00 GMT</pubDate>
<description>WATERTOWN, Mass., September 29, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced positive topline data from RSVHR, a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of zelicapavir in outpatient adults with acute RSV infection who are at high risk of complications including the elderly and/or those wit</description>
</item>
<item>
<title>Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-present-topline-results-200100002</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-present-topline-results-200100002</guid>
<pubDate>Fri, 26 Sep 2025 20:01:00 GMT</pubDate>
<description>WATERTOWN, Mass., September 26, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults.</description>
</item>
<item>
<title>Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-announces-passing-beloved-100000636</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-announces-passing-beloved-100000636</guid>
<pubDate>Wed, 03 Sep 2025 10:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., September 03, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.</description>
</item>
<item>
<title>Enanta Pharmaceuticals to Participate in September Investor Conferences</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-participate-september-investor-110000370</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-participate-september-investor-110000370</guid>
<pubDate>Thu, 21 Aug 2025 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., August 21, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in three investor conferences in September:</description>
</item>
<item>
<title>Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union</title>
<link>https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-files-patent-infringement-110000211</link>
<guid isPermaLink="true">https://6ix.com/company/enanta-pharmaceuticals-inc/news/enanta-pharmaceuticals-files-patent-infringement-110000211</guid>
<pubDate>Wed, 20 Aug 2025 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., August 20, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the ’265</description>
</item>
</channel>
</rss>